II. AMENDMENTS TO THE CLAIMS

1. (Currently amended) A composition for the percutaneous administration of an opioid analgesic which comprises a therapeutic amount of the opioid analgesic in association with a vehicle for providing a transdermal flux of the opioid analgesic when applied to a human body surface or membrane and a quantity of a distressing substance which is non-permeant through human skin, **or is made non-permeant through human skin,** said distressing substance when ingested orally or as parenteral bolus injection together with the opioid analgesic will produce a distressful reaction in the recipient.

2. (Previously amended) A composition for the percutaneous administration of an opioid analgesic which comprises a therapeutic amount of the opioid analgesic in association with a vehicle for providing a transdermal flux of the opioid analgesic when applied to a human body surface or membrane, a quantity of a distressing substance and a membrane which is permeable to the opioid analgesic and non-permeable to the distressing substance, said distressing substance not penetrating the skin of a human patient when the composition is applied to the skin of said patient and said distressing substance when ingested orally or as parenteral bolus injection together with the opioid analgesic will produce a distressful reaction in the recipient.

3. (Previously amended) A composition according to claim 1 , wherein the distressing substance is selected from the group consisting of emetics, nauseants and flavouring substances.

4. (Previously amended) A composition according to claim 2, wherein the distressing substance is selected from the group consisting of ergolides, quatenary ammonium compounds, opioid antagonists, emetics, and atropine or salts thereof.

5. (Previously amended) A composition according to claim 1, wherein the distressing substance is incorporated in a vehicle being the same vehicle as for the opioid analgesic.

6. (Original) A composition according to claim 5, wherein the vehicle includes a penetration enhancer.

7. (Previously amended) A composition according to claim 1, wherein the opioid analgesic is selected from the group consisting of morphine, hydromorphone, buprenorphine, ketamine, fentanyl, tramadol, or pharmaceutically acceptable and percutaneously transmissible salts thereof.

8. (Previously amended) A composition according to claim 1 wherein the opioid analgesic is a narcotic opioid analgesic.

9. (Previously amended) A composition according to claim 1, wherein the opioid analgesic is in an aqueous and/or alcoholic solution, or incorporated in a matrix including a pressure sensitive adhesive.

C1 cont.

10. (Previous amended) A transdermal device containing a composition according to claim 1.

11. (Original) A device according to claim 10, which is an adhesive matrix patch and comprises an impermeable backing layer, a matrix layer which contains the opioid analgesic and a penetration enhancer and distressing substance.

12. (Original) A device according to claim 10, which is a reservoir device.

13. (Previously Amended) A device according to claim 10, which is a monolithic patch.

14. (Previously amended) A composition according to claim 1, which contains buprenorphine or pharmaceutically acceptable salt thereof as the opioid analgesic and atropine or pharmaceutically acceptable salt thereof, or an ergolide or pharmaceutically acceptable salt thereof as the distressing

substance.

15. (Previously added) A device according to claim 10, which contains buprenorphine or pharmaceutically acceptable salt thereof as the opioid analgesic and atropine or pharmaceutically acceptable salt thereof, or an ergolide or pharmaceutically acceptable salt thereof as the distressing substance.

16. (Previously added) A composition according to claim 2, wherein the distressing substance is incorporated in a vehicle being the same vehicle as for the opioid analgesic.

17. (Previously added) A composition for the percutaneous administration of an opioid analgesic which comprises a therapeutic amount of the opioid analgesic in association with a vehicle for providing a transdermal flux of the opioid analgesic when applied to a human body surface or membrane, and a quantity of a distressing substance selected from the group consisting of ergolides, quaternary ammonium compounds, atropine or salts thereof, and mixtures thereof, said distressing substance separated from the opioid analgesic and not penetrating the skin of a human patient when the composition is applied to the skin of said patient, said distressing substance when ingested orally or as parenteral bolus injection together with the opioid analgesic will produce a distressful reaction in the recipient.